Santen Pharmaceutical

Santen Pharmaceutical SNPHF Stock

$13.01   0.000000%
Add to favorites
Market Cap
$4.19B
LOW - HIGH [24H]
$10.99 - $10.99
VOLUME [24H]
$2.00K
P/E Ratio
17.11
Earnings per share
$0.76
ISIN
JP3336000009
Price   Prediction

Santen Pharmaceutical Price Chart

Sorry, that's all we've gotfor now...

Santen Pharmaceutical (SNPHF) stock price today is 13.01 USD on OTC Markets OTCPK (0% on the day). Updated .

Santen Pharmaceutical SNPHF Financial and Trading Overview

Santen Pharmaceutical stock price 13.01 USD
Previous Close 13.01 USD
Open 10.99 USD
Bid 12.52 USD x 30000
Ask 13.34 USD x 30000
Day's Range 10.99 - 10.99 USD
52 Week Range 9.51 - 13.06 USD
Volume 2K USD
Avg. Volume 87 USD
Market Cap 4.19B USD
Beta (5Y Monthly) 0.242
PE Ratio (TTM) 17.118422
EPS (TTM) 0.76 USD
Forward Dividend & Yield 0.26 (2.02%)
Ex-Dividend Date March 30, 2027
1y Target Est N/A

SNPHF Valuation Measures

Enterprise Value -78423662592 USD
Trailing P/E 17.118422
Forward P/E 18.069445
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 0.014093804
Price/Book (mrq) 2.175865
Enterprise Value/Revenue -0.264
Enterprise Value/EBITDA -1.191

Trading Information

Santen Pharmaceutical Stock Price History

Beta (5Y Monthly) 0.242
52-Week Change 28.68%
S&P500 52-Week Change 10.51%
52 Week High 13.06 USD
52 Week Low 9.51 USD
50-Day Moving Average 12.48 USD
200-Day Moving Average 11.7 USD

SNPHF Share Statistics

Avg. Volume (3 month) 87 USD
Avg. Daily Volume (10-Days) 460 USD
Shares Outstanding 321.78M
Float 315.12M
Short Ratio N/A
% Held by Insiders 2.92%
% Held by Institutions 50.52%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 19
Trailing Annual Dividend Yield 146.04%
5 Year Average Dividend Yield 237.00%
Payout Ratio 0.33310002
Last Split Factor 5:1

Financial Highlights

Fiscal Year

Fiscal Year Ends March 31, 2026
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End March 31, 2027

Profitability

Profit Margin 13.08%
Operating Margin (ttm) 16.06%
Gross Margin 59.00%
EBITDA Margin 22.16%

Management Effectiveness

Return on Assets (ttm) 7.38%
Return on Equity (ttm) 13.58%

Income Statement

Revenue (ttm) 297.03B USD
Revenue Per Share (ttm) 923.9 USD
Quarterly Revenue Growth (yoy) 7.50%
Gross Profit (ttm) 175.25B USD
EBITDA 65.84B USD
Net Income Avi to Common (ttm) 38.87B USD
Diluted EPS (ttm) 0.76
Quarterly Earnings Growth (yoy) 2.39%

Balance Sheet

Total Cash (mrq) 81.66B USD
Total Cash Per Share (mrq) 253.77 USD
Total Debt (mrq) 0 USD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 2.97
Book Value Per Share (mrq) 5.9792314

Cash Flow Statement

Operating Cash Flow (ttm) 49.64B USD
Levered Free Cash Flow (ttm) 26.41B USD

Profile of Santen Pharmaceutical

Country United States
State N/A
City Kita
Address Grand Front Osaka Tower A
ZIP 530-8552
Phone 81 6 7664 8621
Website https://www.santen.com/en
Industry Drug Manufacturers - General
Sector(s) Healthcare
Full Time Employees 3968

Santen Pharmaceutical Co., Ltd. engages in the research and development, production, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. The company operates through Medical drugs, Over-the-counter drugs, Medical equipment, and others segments. It products include Taflupro/Timolol maleate, a combination drug of a prostaglandin Fa derivative and a beta-blocker for the treatment of glaucoma and ocular hypertension area; omidenepagisopropyl, an EP2 receptor agonist that is in phase II clinical trial for the treatment of glaucoma and ocular hypertension area; cepetaprost, an FP/EP3 receptor agonist that is in phase II clinical trial for the treatment of glaucoma and ocular hypertension area; latanoprost, a prostaglandin Fa derivative emulsified eye drops; netalusdil mesylate, a ROCK/NET inhibitor; Netalus, a combination drug of a ROCK inhibitor and a prostaglandin Fa derivative; netalusdyl mesialate/latanoprost, a combination drug of a ROCK inhibitor and a prostaglandin Fa derivative that is in phase I clinical trial for the treatment of glaucoma and ocular hypertension area. The company also provides cyclosporine, which is used for vernal catarrhal infections; olodaterol hydrochloride, used for dry eye that is in late-stage Phase 11 trial for the treatment of Keroconjunctival disease; olodaterol hydrochloride, used for allergic conjunctivitis that is in the Phase I/Early Phase II trial for the treatment of Keroconjunctival disease; epinastine hydrochloride, an eyelid cream formulation for allergic conjunctivitis; epinastine, a high-dose eye drop formulation for allergic conjunctivitis; nintedanib, a drug targeting pterygium that is in late-stage Phase II trial for the treatment of Keroconjunctival disease; and eflimrufuspalfa, which is used for diabetic macular edema. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Kita, Japan.

Q&A For Santen Pharmaceutical Stock

What is a current SNPHF stock price?

Santen Pharmaceutical SNPHF stock price today per share is 13.01 USD.

How to purchase Santen Pharmaceutical stock?

You can buy SNPHF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Santen Pharmaceutical?

The stock symbol or ticker of Santen Pharmaceutical is SNPHF.

Which industry does the Santen Pharmaceutical company belong to?

The Santen Pharmaceutical industry is Drug Manufacturers - General.

How many shares does Santen Pharmaceutical have in circulation?

The max supply of Santen Pharmaceutical shares is 321.78M.

What is Santen Pharmaceutical Price to Earnings Ratio (PE Ratio)?

Santen Pharmaceutical PE Ratio is 17.11842200 now.

What was Santen Pharmaceutical earnings per share over the trailing 12 months (TTM)?

Santen Pharmaceutical EPS is 0.76 USD over the trailing 12 months.

Which sector does the Santen Pharmaceutical company belong to?

The Santen Pharmaceutical sector is Healthcare.

$2.14T
Total marketcap
$85.64B
Total volume
BTC 58.00%   •   ETH 9.98%
Dominance
Select currency